| Angelo R Racaniello, MD | |
|
308 Willow Ave, Hoboken, NJ 07030-3808 | |
| (919) 425-1565 | |
| (919) 425-0478 |
| Full Name | Angelo R Racaniello |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 42 Years |
| Location | 308 Willow Ave, Hoboken, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962442194 | NPI | - | NPPES |
| 6388108 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MA46152 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Entity Name | Middlesex Emergency Physicians, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811921760 PECOS PAC ID: 9931002854 Enrollment ID: O20040129000034 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Entity Name | Plainfield Emergency Physicians, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309680 PECOS PAC ID: 7719972728 Enrollment ID: O20040419001065 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Entity Name | Emergency Physician Associates Of North Jersey P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497783419 PECOS PAC ID: 7911992326 Enrollment ID: O20040825001558 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Entity Name | City Medical Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568858686 PECOS PAC ID: 6406161306 Enrollment ID: O20150821013274 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angelo R Racaniello, MD 3114 Croasdaile Dr, Suite 200, Durham, NC 27705-2508 Ph: (877) 751-1157 | Angelo R Racaniello, MD 308 Willow Ave, Hoboken, NJ 07030-3808 Ph: (919) 425-1565 |
News Archive
Agile Therapeutics, Inc., a pharmaceutical development company specializing in women's healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile's lead contraceptive patch. Agile's NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive.
Politico Pro examines the reaction to a speech delivered by Melinda Gates, co-chair of the Bill & Melinda Gates Foundation, at a TEDxChange conference in Berlin on April 5.
The same kinds of impulsive behavior that lead some people to abuse alcohol and other drugs may also be an important contributor to an unhealthy relationship with food, according to new research from the University of Georgia.
A new report, titled "Injection Drug Use in Ukraine" and published by the Center for Strategic & International Studies (CSIS), examines the challenges of providing HIV prevention and care services in the country, particularly to people who inject drugs (PWID), who accounted for "nearly 50 percent of new HIV infections registered in 2010," according to the CSIS website.
Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to launch RE-ALIGN, a global, Phase II trial evaluating the safety and pharmacokinetics of dabigatran etexilate in 400 patients who have mechanical heart valves.
› Verified 4 days ago
Dr. Ragini Mehta, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 380 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-1900 | |
Dr. James Caniglia, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 308 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-2065 | |
Dr. Harendra Umangla Mehta, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 308 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-2065 | |
Edward Lawyer, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 308 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-2065 | |
Dr. John Joseph Rimmer Iii, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 308 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-1000 | |
Dr. Eric Douglas Wasilowski, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 122 Jackson St Apt 1a, Hoboken, NJ 07030 Phone: 206-313-0892 | |
Yusef Hassan Sabri Hamid, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 309 Willow Ave, Hoboken, NJ 07030 Phone: 201-418-3125 |